Lilly’s obesity drug looks more potent than Novo’s in observational study

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. STAT published an investigation this morning on the untold story of the Human Genome Project and ethics concerns surrounding the ambitious project. Check it out here.

The need-to-know this morning

• Pfizer Chief Scientific Officer and R&D Chief Mikael Dolsten is leaving the company after 15 years. A search for his successor is expected to last until early next year, the pharma giant said.
• UniQure said its experimental gene therapy called AMT-130 slowed the progression of Huntington’s disease by 80% compared to an external control group in a mid-stage clinical trial.

Interius to start first ever in-vivo CAR-T clinical trial

Interius Biotherapeutics will soon begin the world’s first clinical trial of in-vivo CAR-T therapy. Patients will receive an IV infusion designed to transform their immune cells into cancer killers inside their bodies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In